108 related articles for article (PubMed ID: 14759771)
1. N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression.
Liu HK; Green BD; Gault VA; McCluskey JT; McClenaghan NH; O'Harte FP; Flatt PR
Cell Biol Int; 2004; 28(1):69-73. PubMed ID: 14759771
[TBL] [Abstract][Full Text] [Related]
2. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1.
Green BD; Liu HK; McCluskey JT; Duffy NA; O'Harte FP; McClenaghan NH; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):563-9. PubMed ID: 16050949
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
4. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
5. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness.
Delmeire D; Flamez D; Moens K; Hinke SA; Van Schravendijk C; Pipeleers D; Schuit F
Biochem Pharmacol; 2004 Jul; 68(1):33-9. PubMed ID: 15183115
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site.
Hay CW; Sinclair EM; Bermano G; Durward E; Tadayyon M; Docherty K
J Endocrinol; 2005 Aug; 186(2):353-65. PubMed ID: 16079261
[TBL] [Abstract][Full Text] [Related]
7. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.
Hui H; Zhao X; Perfetti R
Diabetes Metab Res Rev; 2005; 21(4):313-31. PubMed ID: 15852457
[TBL] [Abstract][Full Text] [Related]
8. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
10. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
[TBL] [Abstract][Full Text] [Related]
11. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
12. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
Siegel EG; Scharf G; Gallwitz B; Mentlein R; Morys-Wortmann C; Fölsch UR; Schmidt WE
Eur J Clin Invest; 1999 Jul; 29(7):610-4. PubMed ID: 10411667
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect.
Bulut K; Meier JJ; Ansorge N; Felderbauer P; Schmitz F; Hoffmann P; Schmidt WE; Gallwitz B
Regul Pept; 2004 Sep; 121(1-3):137-43. PubMed ID: 15256284
[TBL] [Abstract][Full Text] [Related]
16. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells.
Abraham EJ; Leech CA; Lin JC; Zulewski H; Habener JF
Endocrinology; 2002 Aug; 143(8):3152-61. PubMed ID: 12130581
[TBL] [Abstract][Full Text] [Related]
17. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
18. Circulation and degradation of GIP and GLP-1.
Deacon CF
Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells.
Hui H; Wright C; Perfetti R
Diabetes; 2001 Apr; 50(4):785-96. PubMed ID: 11289043
[TBL] [Abstract][Full Text] [Related]
20. The role of GLP-1 in the life and death of pancreatic beta cells.
Perfetti R; Hui H
Horm Metab Res; 2004; 36(11-12):804-10. PubMed ID: 15655712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
